Comparison of Type 2 Diabetes Pharmacotherapy Regimens

What this study is testing ClinicalTrials.gov NCT05073692 ↗

Description as written by the study sponsor.

This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.

Treatments tested

• SU Drug

  Exposure to the class of drugs known as Sulfonylureas (SU)

• DPP4 Drug

  Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)

• SGLT2i Drug

  Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)

• GLP-1RA Drug

  Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)

• SGLT2i or GLP-1RA Drug

  Exposure to either SGLT2i or GLP-1RA

• Linagliptin (DPP4) Drug

  Exposure to agent Linagliptin (DPP4)

• Exenatide (GLP-1RA) Drug

  Exposure to agent Exenatide (GLP1-RA)

• Liraglutide (GLP-1RA) Drug

  Exposure to agent Liraglutide (GLP-1RA)

• Empagliflozin (SGLT2i) Drug

  Exposure to agent Empagliflozin (SGLT2i)

• Glimepiride (SU) Drug

  Exposure to agent Glimepiride (SU)

• Glipizide (SU) Drug

  Exposure to Glimepiride (SU)

• Glimepiride (SU) or Glipizide (SU) Drug

  Exposure to agent Glimepiride (SU) or Glipizide (SU)

• SU or DPP4 (excluding saxagliptin and alogliptin) Drug

  Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin

• Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) Drug

  Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)